The application of radionuclide labeling of molecules with high affinity for PSMA in the diagnosis, staging, re-staging and treatment of refractory prostate cancer is increasingly becoming a new strategy for the imaging and treatment of prostate cancer. Here, FOLH1 is linked to prostate carcinoma.